Form 4: Fulgent Genetics CSO Executes Tax-Related Stock Sale

Chief Scientific Officer Hanlin Gao sold 945 shares of Fulgent Genetics to cover tax obligations related to RSU vesting.

Summary

• Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc., sold 945 shares of common stock.
• The transaction occurred on May 27, 2026, at a weighted-average price of $17.60 per share.
• The sale was conducted to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs).
• Following this transaction, the reporting person retains beneficial ownership of 992,062 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to satisfy tax obligations rather than a discretionary divestment.

Positives

• The sale was non-discretionary, specifically executed to cover tax liabilities associated with equity compensation.

Negatives

• The transaction represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling, even for tax purposes, can sometimes be perceived negatively by retail investors regardless of the underlying intent.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine tax-related selling by executives is a standard corporate practice and typically does not signal a change in management's confidence regarding the company's long-term prospects.

Comparison to Industry Standards

• The transaction aligns with standard industry practices for executive compensation management.
• The use of sell-to-cover transactions is a common mechanism for managing tax liabilities in the biotechnology and healthcare sectors.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was limited in size and purpose-driven.

Key Dates

Keywords

Fulgent Genetics, FLGT, Insider Trading, Form 4, Chief Scientific Officer, Equity Compensation